The predictive value of centre tumour CD8+ T cells in patients with hepatocellular carcinoma: Comparison with Immunoscore

Oncotarget

Volumn 6, Issue 34, 2015, Pages 35602-35615

  Sun, Cheng ^a,b   Xu, Jing ^c   Song, Jiaxi ^a   Liu, ChaoQun ^c   Wang, Jinyu ^a   Weng, Chenchun ^a   Sun, Haoyu ^a   Wei, Haiming ^a   Xiao, Weihua ^a   Sun, Rui ^a,b   Tian, Zhigang ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

CD8+ T cells; HCC; Immunoscore; Prognostic indicator; TNM

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSCORE; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROCEDURES CONCERNING CELLS; PROSPECTIVE STUDY; SCORING SYSTEM; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

AGED; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOLOGIC TESTS; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; T-LYMPHOCYTE SUBSETS;

EID: 84946893368     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5801     Document Type: Article

References (32)

1. Mlecnik B, Bindea G, Pages F and Galon J. Tumor immunosurveillance in human cancers. Cancer metastasis reviews. 2011; 30:5-12.
2. Nagtegaal ID, Quirke P and Schmoll HJ. Has the new TNM classification for colorectal cancer improved care? Nature reviews Clinical oncology. 2012; 9:119-123.
3. Emens LA, Silverstein SC, Khleif S, Marincola FM and Galon J. Toward integrative cancer immunotherapy: targeting the tumor microenvironment. Journal of translational medicine. 2012; 10:70.
4. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, et al. Cancer classification using the Immunoscore: a worldwide task force. Journal of translational medicine. 2012; 10:205.
5. Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF and Ascierto PA. The immune score as a new possible approach for the classification of cancer. Journal of translational medicine. 2012; 10:1.
6. Angell H and Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Current opinion in immunology. 2013; 25:261-267.
7. Galon J, Angell HK, Bedognetti D and Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013; 39:11-26.
8. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. The Journal of pathology. 2014; 232:199-209.
9. Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J and Fox BA. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. Journal of translational medicine. 2013; 11:54.
10. Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, Kirilovsky A, Lagorce C, Bindea G, Ferariu D, Danciu M, Bruneval P, Scripcariu V, Chevallier JM, Zinzindohoue F, Berger A, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20:1891-1899.
11. Ikeguchi M, Oi K, Hirooka Y and Kaibara N. CD8+ lymphocyte infiltration and apoptosis in hepatocellular carcinoma. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2004; 30:53-57.
12. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313:1960-1964.
13. Galon J, Fridman WH and Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer research. 2007; 67:1883-1886.
14. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ and Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A. 2007; 104:3967-3972.
15. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y and Hiraoka N. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013; 108:914-923.
16. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102:18538-18543.
17. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T and Fujii S. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007; 104:3360-3365.
18. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO and Green AR. Tumorinfiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29:1949-1955.
19. Karja V, Aaltomaa S, Lipponen P, Isotalo T, Talja M and Mokka R. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res. 2005; 25:4435-4438.
20. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H and Ohtani H. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer research. 2001; 61:5132-5136.
21. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S and Ochiai A. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008; 113:1387-1395.
22. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005; 353:2654-2666.
23. Schumacher K, Haensch W, Roefzaad C and Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer research. 2001; 61:3932-3936.
24. Wada Y, Nakashima O, Kutami R, Yamamoto O and Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998; 27:407-414.
25. Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, Fan J and Tang ZY. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006; 132:293-301.
26. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW and Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25:2586-2593.
27. Taube JM. Emerging immunologic biomarkers: setting the (TNM-immune) stage. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20:2023-2025.
28. Brunner SM, Rubner C, Kesselring R, Martin M, Griesshammer E, Ruemmele P, Stempfl T, Teufel A, Schlitt HJ and Fichtner-Feigl S. Tumor-infiltrating, interleukin-33-producing effector-memory CD8 T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology. 2015.
29. Takata Y, Nakamoto Y, Nakada A, Terashima T, Arihara F, Kitahara M, Kakinoki K, Arai K, Yamashita T, Sakai Y, Mizukoshi E and Kaneko S. Frequency of CD45RO+ subset in CD4+CD25(high) regulatory T cells associated with progression of hepatocellular carcinoma. Cancer Lett. 2011; 307:165-173.
30. Sun C, Sun H, Zhang C and Tian Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol. 2015; 12:292-302.
31. Sun C, Sun HY, Xiao WH, Zhang C and Tian ZG. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin. 2015.
32. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M and Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97:1180-1184.